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Edited by Jesus AvilaAbstract Serum withdrawal rapidly induces apoptosis in rat
423-cells, while addition of bFGF results in cell survival.
However, surviving cells initially display morphological changes
characteristic for apoptotic cells and even process caspases.
Active caspase-3 was detected at the single-cell level in those
ﬁnally bFGF-rescued cells, while mitochondrial integrity was
maintained. Generation of cleavage products of caspase targets
was conﬁrmed in surviving cells. Proteome analysis indicated
multi-faceted survival activities of bFGF including upregulation
of inhibitor-of-apoptosis and heat shock protein family members
directly interfering with caspases. Our data suggest that the
‘‘point-of-no-return’’ in death-induced cells has to be moved
downstream of activated caspase-3.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The homeostasis of each tissue, and thus of an entire or-
ganism, is regulated by the balance between cell proliferation
and apoptosis, a form of programmed cell death. This is
characterised by morphological changes like cell shrinkage,
membrane blebbing, detachment and ﬁnally fragmentation of
cell content into vesicles. The progress of apoptosis is well
concerted in a spaciotemporal manner by a cascade of death
speciﬁc proteases, termed caspases [1]. In this cascade initiator
caspases activate executioner caspases. To ensure proper per-
formance of death signalling, a sophisticated caspase network
exists [2]. Once, executioner caspases are activated, they cleave
cellular target proteins, most of them with a discrete function
in propagation of cell death processes [3]. Distinct safety steps
to prevent aberrant caspase activation were implemented
during evolution. Most directly, inhibitor-of-apoptosis pro-
teins (IAP) block processing of caspases and inhibit also pro-* Corresponding author. Fax: +43-1-4277-9651.
E-mail address: chantal.schamberger@meduniwien.ac.at
(C.J. Schamberger).
Abbreviations: bFGF, basic ﬁbroblast growth factor; IAP, inhibitor-
of-apoptosis protein; IF, intermediate ﬁlament; IL, interleukine; hsp,
heat shock protein; NSCLC, non-small cell lung cancer; ROS, reactive
oxygen species; TNFR, tumour necrosis factor receptor
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shock protein (hsp) family interfere with apoptotic pathways
and prevent caspase cleavage [5]. Another important event is
to preserve the integrity of intracellular membranes like mi-
tochondria and the endoplasmatic reticulum by anti-apoptotic
bcl-family members [6]. Some intermembrane space proteins
can induce or enhance caspase activation, whereas others
might act in a caspase-independent manner to promote ap-
optosis [7]. This ﬁne-tuned cellular equilibrium between life
and death is overbalanced not only upon triggering apoptosis,
but also by the addition of survival factors, like basic ﬁbroblast
growth factor (bFGF). bFGF plays an important role in cell
proliferation, diﬀerentiation, neoangiogenesis and survival in
various tissues and cell systems, but also malignancies [8]. The
abundance of this ubiquitary expressed growth factor con-
tributes to resistance in chemotherapy and enhances survival
of malignant cells [9–11].
We took advantage of a rat cell line, 423-cells, that undergo
apoptosis upon serum withdrawal in a caspase-dependent
manner within a few hours, while bFGF was described as
potent survival factor for this cell culture model system [12].
Despite morphological alterations and even caspase-3 activa-
tion, bFGF-treated 423-cells escape from termination phase of
apoptosis. The purpose of the present study was to determine
how far apoptotic signalling proceeded under the inﬂuence of
the survival factor bFGF and to characterise these survival
eﬀects by means of proteome analysis.2. Materials and methods
2.1. Chemicals and antibodies
Antibodies directed against caspase-3, nPKC-d and survivin were
supplied by Santa Cruz, caspase-8 by NeoMarkers, vimentin and b-
actin by Sigma, c-IAP-1 and PARP (C2-10) by R&D, and cleaved
caspase-3-p17 by New England Biolabs. Peroxidase-secondary anti-
bodies and Cy3-conjugated anti-rabbit antibody were purchased from
Calbiochem. 40-6-Diamidine-2-phenyl indole (DAPI), JC-1 and bFGF
from Calbiochem, caspase dye, Di-L-aspartate-rhodamine 110 (D2R)
from Alexis and Complete Protease Inhibitor Cocktail from Roche
Diagnostics.
2.2. Cell culture
The non-transformed, G418-resistant embryonic rat cell line, 423,
immortalised by Human Papilloma Virus type 11 DNA [13], was
routinely cultivated in DMEM/10% FCS, penicillin/streptomycin (100
U/ml) and G418 (200 lg/ml). For induction of apoptosis, conﬂuent
cultures of 423-cells were washed twice with serum-free DMEM and
further incubated in DMEM/0.1% FCS. bFGF (25 ng/ml) was added
at the time point of serum withdrawal.blished by Elsevier B.V. All rights reserved.
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For total protein lysates, cells were harvested by scraping, washed
twice in ice cold PBS and lysed in RIPAII (500 mMNaCl; 50 mM Tris,
pH 7.4; 0.1% SDS; 1% NP-40; 0.5% Na-DOC; 0.05% NaN3 and
complete protease inhibitor mix) for 30 min on ice. Lysates were
soniﬁcated, centrifuged at 12 000· g. Supernatants were used as total
cell lysates. SDS–PAGE and Immuno Blot procedure was performed
as described in [14].
2.4. Immunoﬂuorescence and FACS analysis
423-cells were plated on coverslips and cultivated in the appropriate
media for at least 48 h before ﬁxation. Serum withdrawal in the
presence or absence of bFGF was performed for 4 h. Cells were ﬁxed
and stained with anti-cleaved caspase-3/anti-rabbit-Cy3 and DAPI as
described in [14].
423-cells were seeded in 24-well plates and apoptosis was induced up
to 6 h. Twenty minutes before harvesting ﬂoating and attached cells
together, D2R was added to the medium [15]. For determination of
mitochondrial integrity, ﬂoating and attached cells were combined in
DMEM, 2.5% FCS and stained with 5 lM JC-1 for 10 min in the dark
[16,17]. Samples were analysed in a Becton Dickinson FACSCalibur
system using CELLQuest software.
2.5. Metabolic labelling and two-dimensional electrophoresis
Labelling, fractionation, isoelectric focusing, SDS–PAGE, autora-
diography and silver staining were performed as previously described
[18]. Brieﬂy, conﬂuent 423-cells were washed in serum-free medium
and further incubated in methionine-free medium containing 10% FCS
(control cells), 0.1% FCS (apoptotic cells) and 0.1% FCS plus bFGF
(surviving or rescued cells), respectively. Labelling occurred by addi-
tion of 0.8 mCi/107 cells 35S-protein labelling mix (NEG-072, Perkin-
Elmer Life Sciences) at the time point of medium change. After a 4 h
labelling time, cells were collected by centrifugation, fractionated and
100 lg protein were separated and comparative gel analysis was per-
formed using the 2-D Analyzer V 6.1 software package. Identiﬁca-Fig. 1. Serum withdrawal in the presence or absence of bFGF. (A) bFGF-tre
and by DAPI staining (right panel) during a time course. Morphological
apoptosis and bFGF-mediated rescue at 2 h. At 12 h bFGF-treated 423-cells
and apoptotic bodies were detected in untreated cells (upper panel). Condense
vimentin as indicator for cytoskeletal breakdown during bFGF-mediated r
presence or absence of bFGF during a time course was performed by Wester
with remodelling of morphology. Caspase-speciﬁc vimentin fragment is martion of protein spots by mass spectrometry ﬁngerprinting was
performed as described in [18].3. Results
3.1. Serum withdrawal in the absence and presence of bFGF
We compared 423-cells induced to undergo apoptosis with
the bFGF-treated, ﬁnally surviving cells. Monitoring the
morphological changes after serum withdrawal by light mi-
croscopy (Fig. 1A); we found that 423-cells rounded up rap-
idly, irrespective of bFGF addition. At 2 h after serum
deprivation, bFGF-treated cells were undistinguishable from
those committed for apoptosis. However, the apoptotic cell
population already displayed some DNA condensation, while
bFGF-treated cells did not (Fig. 1A, white arrows). Blebbing
and massive cell detachment started after 3 h and preceded
further in the apoptotic 423-cells, but remained undetectable in
the bFGF-treated cells. Furthermore, the bFGF-rescued cells,
still maintained in low serum conditions, reattached between
the forth and ﬁfth hour and ﬁnally completed restructuring of
the conﬂuent layer without any signs of apoptosis 12 h after.
As the morphology of 423-cells was apparently destroyed
within minutes after serum withdrawal, we looked for a mar-
ker for cytoskeletal disruption. The intermediate ﬁlament (IF)
protein vimentin is a caspase target [19], like other cytoskeletal
proteins as cytokeratins [20] and myosin heavy chain [18]. In
contrast to monomeric vimentin, the ﬁlamentous form is
highly insoluble in commonly used lysis buﬀers [21], and mayated and untreated 423-cells were imaged by phase contrast (left panel)
alterations, spherical cells, occurred during serum starvation-induced
recovered (lower panel), while a mixture of remaining cells in the layer
d nuclei are marked by white arrows. (B) Intermediate ﬁlament protein
escue. Detection of soluble vimentin in serum-starved 423-cells in the
n analysis. Disappearance of vimentin in bFGF-treated cells correlated
ked by an arrow. Actin was used as loading control.
C.J. Schamberger et al. / FEBS Letters 573 (2004) 19–25 21hence remain hardly detectable by Western analysis. We
analysed vimentin in 423-cells after serum withdrawal in a time
course in the absence or presence of bFGF, respectively
(Fig. 1B). In untreated attached cells only low level of vimentin
was detectable, but the amount increased upon serum with-
drawal, irrespective of bFGF supplement, correlating with
shrunken morphology of the cells. Under apoptotic condition,
vimentin cleavage occurred within 3 h, whereas in bFGF-
treated cultures no cleavage was observed. Three hours after
bFGF treatment, when cells started to reattach, detectable
vimentin levels started to decrease rapidly, indicative of re-
building of the ﬁlamentous network. These morphological and
biochemical observations suggested that early apoptotic events
upon serum withdrawal proceeded regardless of the presence
of a potent survival factor.
3.2. Caspases processing despite the presence of bFGF
To investigate how far apoptosis proceeds in the presence of
bFGF, we performed a time course of caspases processing
(Fig. 2). Intriguingly, caspase-8 and subsequently caspase-3
were processed upon serum withdrawal in the absence but also
in the presence of bFGF. In bFGF-treated cells, caspase-3
processing was weaker and the cleaved fragment became un-
detectable within 5 h. In order to determine proteolytic activity
of the processed caspases, we investigated the cleavage of a
cytoplasmic and a nuclear caspase-3 target, nPKC-d and
PARP. Indeed, cleavage fragments of both caspase targets
were detected in the surviving cell population treated withFig. 2. Activation of caspases in serum-starved and bFGF-treated 423-cells d
caspase-3 was evidenced by detection of characteristic cleavage products, on
in the presence and absence of bFGF. Cleavage products are marked by arrbFGF. These data suggested that caspase processing and ac-
tivation was actually triggered upon serum withdrawal in the
presence of a potent survival factor eventually resulting in cell
survival.
3.3. Caspases are uniformly activated upon serum withdrawal
regardless of bFGF treatment
The question arose, whether the detected caspase cleavage
products might derive from a small minority of dying cells
within the bulk of surviving bFGF-treated 423-cells. There-
fore, we analysed caspase activity at single cell level by ﬂuo-
rescence detection of the Rhodamine-linked caspase substrate
dye D2R [15] in 423-cells in the presence and absence of bFGF
upon serum withdrawal. Under apoptotic and surviving con-
ditions, similar amounts of cells processed this caspase-speciﬁc
dye within the ﬁrst 2 h (Fig. 3A). Elevated caspase activity in
bFGF-treated cells (Fig. 3A, open circles) may reﬂect contri-
bution of maybe apoptosis-independent caspases, other than
caspase-8 and -3 (compare to Fig. 2). After 4 h the percentage
of bFGF-treated, serum starved cells with caspase activity
decreased, while the fraction of serum starved cells with cas-
pase activity (Fig. 3A, ﬁlled circles) remained constant. As a
second approach, we performed immunoﬂuorescence in un-
treated, apoptotic and surviving 423-cells with an antibody
speciﬁc for cleaved caspase-3 (Fig. 3B). Importantly, cleaved
caspase-3 was detectable in similar amounts in apoptotic and
surviving cells, but not in untreated controls. Taken together,
the apoptotic machinery was found switched on upon serumuring a time course. Processing of caspase-8 and subsequently that of
both conditions. PARP and nPKCd, as caspase-3 targets, were cleaved
ows. Actin was used as loading control.
Fig. 3. Caspase activation, but maintenance of mitochondrial integrity
in bFGF-rescued 423-cells. (A) Measurement of general caspase-ac-
tivity by R2D. Caspase activity, measured by Rhodamine-ﬂuorescence,
was determined by FACS analysis after serum starvation in the ab-
sence (ﬁlled circles) or presence (open circles) of bFGF in a time course
up to 6 h. The bars represent S.D. from at least three independent
experiments. (B) Evaluation of cleaved caspase-3. Immunoﬂuorescence
with cleaved caspase-3-speciﬁc antibody was performed 3 h after serum
starvation in the presence or absence of bFGF and in 423-control cells.
Nuclei were counterstained with DAPI. (C) Preservation of mito-
chondrial integrity by bFGF. Mitochondrial integrity, measuring a
ﬂuorescence shift of the mitochondrial dye JC-1, was determined by
FACS analysis after serum starvation in the absence (ﬁlled circles) or
presence (open circles) of bFGF in a time course up to 6 h. The bars
represent S.D. from at least three independent experiments.
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apoptotic eﬀects of bFGF may act downstream of activated
execution caspases.
3.4. bFGF preserves mitochondrial integrity
Mitochondria are an important part of the apoptotic ma-
chinery. Mitochondrial damage promotes apoptosis in two
ways. On the one hand, it leads to the release of apoptogenic
factors [7] and, on the other hand, it disrupts energy produc-
tion of the cell. We examined changes in mitochondrial
membrane potential by ﬂow cytometric analysis of JC-1
complexes [17] during a time course after serum withdrawal in
the absence and presence of bFGF. The percentage of 423-cells
with low mitochondrial membrane potential increased from abasal level of 10% up to 35% after 6 h at apoptotic conditions
(Fig. 3C, ﬁlled circles), while bFGF-treated 423-cells (Fig. 3C,
open circles) maintained mitochondrial integrity.
3.5. Cleavage of a subset of proteins in bFGF-rescued 423-cells
Caspase-3 was found activated in surviving cells, but its
proteolytic activity was apparently intercepted to circumvent
irreversible commitment for apoptosis. Therefore, we screened
for possible diﬀerences of caspase activity at apoptotic and
surviving conditions. We compared the cytoplasmic fraction at
a 4-h time point of control, apoptotic and bFGF-treated 423-
cells by proteome analysis. As expected, several caspase-gen-
erated cleavage products of most notably cytoskeletal proteins
including actin, fodrin, cytokeratin 19, myosin heavy chain
and vimentin were detected in apoptotic 423 cells (Fig. 4C),
but not in controls (Fig. 4A). Intriguingly, only a subset of
cytoskeletal proteins including actin and vimentin were found
partially degraded in bFGF-treated cells (Fig. 4E).
3.6. Induction of inhibitor-of-apoptosis proteins and heat shock
proteins in death-induced, but bFGF-rescued 423-cells
To elucidate mechanisms involved in the anti-apoptotic ca-
pability of bFGF, we investigated the cytoplasmic protein
expression proﬁle of 35S-radiolabelled cells at the same time
point. 35S-incorporation was found strongly decreased in ap-
optotic cells (Fig. 4D) compared to controls, and partially
restored in bFGF-treated cells (Fig. 4E). Several proteins, in-
cluding calreticulin, c-IAP-1, antiox2, grp78, hsp27 and SOD
were signiﬁcantly upregulated by bFGF (Fig. 4F compared to
4D, Table 1). Upregulation of cellular caspase inhibitor pro-
tein c-IAP-1 was veriﬁed by Western analysis. In addition, a
second member of the IAP family, survivin, was found induced
by bFGF (Fig. 5). Another family of anti-apoptotic proteins,
hsps, were aﬀected in diﬀerent ways. Hsp70 expression was
found upregulated and hsp27 phosphorylated at apoptotic
conditions. Soluble cytoplasmic hsp90 became undetectable in
bFGF-rescued cells, and was found translocated to the nuclear
compartment (data not shown), comparable to translocation
in fas-induced Jurkats [22]. These data suggest that bFGF may
mediate cell survival by direct caspase inhibition via upregu-
lation and activation of anti-apoptotic proteins.4. Discussion
Escape from apoptosis is not only a prerequisite for early
stages of transformation processes, but also a major obstacle
in cancer therapy. bFGF, a growth factor frequently expressed
in normal tissues and overexpressed in carcinomas [23], can
mediate strong survival beneﬁt. In this study, we demonstrated
that bFGF was capable to counteract late apoptotic events,
including caspase-3 activity. Upon serum withdrawal, apop-
tosis was rapidly induced in rat 423-cells. While initial mor-
phological alterations were found unaﬀected, bFGF prevented
membrane blebbing and DNA fragmentation (Fig. 1A). Pro-
cessing of initiator caspase-8 was similar in apoptotic and
bFGF-rescued cells (Figs. 2 and 3A). Caspase-3 processing
was reduced in bFGF-treated cells, but still resulted in the
cleavage of target proteins. The unexpected ﬁnding of caspase-
3 activation without subsequent cell death was already de-
scribed for T lymphocytes stimulated with interleukine (IL)-2
or phytohaemaglutinin A [24–26], ras-overexpressing Ba/F3
Fig. 4. Expression proﬁling of apoptosis-induced, but bFGF-rescued cells. Silver stained 2D-gels of cytoplasmic fractions of control, apoptotic (4 h)
and bFGF-rescued (4 h) of 35S-radiolabelled 423-cells (A, C and E) and the corresponding autoradiographs (B, D and F) reveal caspase activities and
bFGF-survival eﬀects, respectively. Cleaved and altered proteins are encircled and annotated.
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(NSCLC) upon irradiation and etoposide treatment [28]. In
NSCLC, only cytoplasmic targets were aﬀected, while in he-
matopoetic cells cleavage of nuclear caspase targets, such as
PARP and lamin B, also occurred. In surviving 423-cells, cy-
toplasmic and nuclear caspase targets were found cleaved
(Figs. 2 and 4). We performed comparative proteome analysis
of control, apoptotic and bFGF-rescued 423-cells to gain in-
sight into the multi-faceted survival activities of bFGF. Taken
together, the following events were observed:1. Induction and upregulation of IAP and heat shock protein
family members to counteract caspase activities.
2. Upregulation of chaperones to facilitate protein repair.
3. Upregulation of proteins involved in reactive oxygen spe-
cies metabolism.
4. Preservation of mitochondrial integrity to maintain cellular
energy supply.
5. Restoration of cellular morphology after initial crisis.
IAP [29] and hsp [4], most notably hsp70 [30], may act as
emergency brake to inhibit further proteolytic caspase activity.
Table 1
Proteins aﬀected during apoptosis and bFGF-mediated survival
Protein name Accession
No.
Apoptotic
vs. control
bFGF
vs. control
bFGF
vs. apoptotic
Identiﬁcation
Actin P60711 Cleaved Cleaved – W, MS
Calreticulin P18418 Down Down Up MS
Grp78 P06761 Down Down Up MS
Heat shock protein hsp90-b (hsp90) P34058 – Transl. Transl. W
Heat shock protein b-1 (hsp27) P42930 Phosh. – Up W, MS
Heat shock 70 kDa protein 1/2 (hsp70) Q07439 Up Up Up W
Inhibitor-of-apoptosis protein 1 (c-IAP-1) Q9ESE9 down Up Up W
Keratin, type I cytokeratin 19 Q63279 Cleaved Cleaved – MS
Laminin binding precurser (LBP-p40) P38983 Cleaved Cleaved – MS
Myosin heavy chain, non-muscle type A (NMMHC) Q62812 Cleaved – – MS
Peroxiredoxin 6 (antiox2) O35244 Down Down Up MS
Spectrin a chain (fodrin) P16086 Cleaved – – MS
Superoxide dismutase [Cu–Zn] (SOD) P07632 Down Down Up MS
Vimentin P31000 Cleaved Cleaved – W
List of altered proteins during apoptosis and bFGF-mediated survival in 423-cells. – , unaﬀected; Cleaved, caspase-cleavage products; Down,
downregulated; Phosph., phosphorylated; Transl., translocated; Up, upregulated; MS, mass spectrometry ﬁngerprinting; W, Western blot.
Fig. 5. bFGF induces IAP expression. Total protein lysates were prepared from control, serum-starved and bFGF-treated, serum-starved 423-cells
during a time course. Induction of IAPs proceed after bFGF treatment, solely. bFGF-mediated c-IAP-1 upregulation and induction of survivin
expression indicated regression of caspase activation. Actin was used as loading control.
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bFGF-rescued 423-cells. c-IAP-1 was described as tumour
necrosis factor receptor (TNFR2)-associated protein partici-
pating in TNFR signalling complexes and interfering with
caspase-8 activation [31,32]. In addition, it was found to di-
rectly inhibit the executioner caspases, caspase-3 and -7 [33].
Recently, we showed that the strict cell-cycle-regulated ex-
pression of survivin can be deregulated by oncogenic c-H-ras
[14]. Likewise, during bFGF-mediated survival, survivin was
apparently upregulated independent from re-entry into cell
cycle. We found no changes in cell cycle distribution during the
ﬁrst hours upon serum withdrawal and bFGF addition (data
not shown). Intriguingly, hsp70 was also strongly upregulated
under apoptotic conditions, suggesting a general stress re-
sponse upon serum withdrawal not suﬃcient for cell survival.
In bFGF-rescued cells, additional members of the hsp family
were increasingly translated, indicative of an enhanced re-
quirement for protein repair [4]. hsp27, a member of the small
hsp family, exerts its chaperone activity solely as oligomer by
preventing aggregation of misfolded proteins [34]. Upon var-
ious stress stimuli, hsp27 becomes phosphorylated, resulting in
the collapse of this chaperone complex, whereby it can no
longer exert anti-apoptotic properties [35]. We observed hsp27phosphorylation upon apoptosis induction, but not in bFGF-
rescued 423-cells. Therefore, circumvention of hsp27 phos-
phorylation and subsequent preservation of its anti-apoptotic
chaperone function may contribute to bFGF-mediated
survival.
Indicative of further repair activity, we found a series of
detoxiﬁcation enzymes upregulated in bFGF-rescued cells.
Free radical-derived reactive oxygen species (ROS) are formed
by incomplete reduction of molecular oxygen and are con-
stantly generated in most living tissue and cells in culture. ROS
can potentially damage lipids, proteins and DNA, but also
lead to reversible oxidation of proteins [36]. Upon growth
factor withdrawal, ROS are produced apparently to enhance
cell death, for example in PC-12 and mouse proximal tubular
cells [37,38]. Therefore, upregulation of antiox2 and SOD,
mediating ROS metabolism, by bFGF (Fig. 4F) may coun-
teract apoptotic ROS production and signalling. Intriguingly,
bFGF-mediated upregulation of antiox2 and SOD was only
observed at serum-deprived, but not at full serum conditions
(data not shown).
Mitochondrial damage enhances apoptosis by the release of
apoptogenic factors [7], disruption of energy production [39]
and subsequent production of ROS [40]. Preservation of mi-
C.J. Schamberger et al. / FEBS Letters 573 (2004) 19–25 25tochondrial integrity mediated by bFGF (Fig. 3) seems to be of
higher priority for successful cell survival than the complete
inhibition of caspase activity.
Intact cellular structures are prerequisite for the function,
proliferation, diﬀerentiation and survival of cells [41]. Break-
down of the structural integrity is a common feature of ap-
optotic cells. Intriguingly, a transient breakdown of cell
architecture was observed in 423-cells struggling with death
(Fig. 1). Consequent to our observations, the ‘‘point-of-no-
return’’ in death-induced cells has to be moved downstream of
activated caspase-3 into the execution phase of apoptosis. Our
data suggest multi-faceted activities of bFGF in order to ﬁ-
nally restore cellular integrity and enable survival.
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